Compare age-related testosterone changes with hypogonadism, including symptoms, repeat testing, SHBG and the health context behind treatment decisions.
Age-related testosterone changes and hypogonadism are not the same thing: the clinical decision is whether a man's findings reflect healthy aging or a hormone deficiency syndrome.
This content is for informational purposes only and is not medical advice. A qualified clinician should assess individual symptoms and make testing or treatment decisions.
The European Association of Urology (EAU) describes a small and gradual testosterone decline in healthy aging men. Its Male Hypogonadism guideline says aging accounts for only a small proportion of hypogonadism. It also states that the decline remains small through age 80.
That is different from saying that getting older inevitably produces a testosterone deficiency. Age-associated change describes a pattern across time. Hypogonadism describes a clinical condition with both symptoms and biochemical evidence.
The EAU guideline cites European Male Aging Study estimates of a 0.4% annual decrease in total testosterone and a 1.3% annual decrease in free testosterone. These are population estimates rather than forecasts for an individual man. They should not be used to calculate what someone's testosterone ought to be at a particular birthday.
The difference between those estimates also makes it important to identify which measurement a discussion concerns. A statement about total testosterone is not interchangeable with a statement about free testosterone.
For men trying to understand a change over time, the useful comparison is therefore more specific than “younger versus older.” It includes the hormone measurement being discussed and the person's health context. According to the EAU, obesity and other illnesses are major contributors to the increasing prevalence of late-onset hypogonadism with age.
The EAU defines male hypogonadism as a clinical syndrome involving symptoms, with or without signs, together with biochemical evidence of testosterone deficiency. In plain language, the assessment must connect how a person is doing with what appropriately interpreted blood tests show.
The guideline reports estimates ranging from 2.1% to 5.7% for symptomatic hypogonadism in men aged 40 to 79. Those estimates concern a defined clinical syndrome within that age group. They are not estimates of how many men experience any symptom sometimes associated with low testosterone.
The EAU distinguishes causes involving testicular function from causes involving inadequate stimulation by the hypothalamic-pituitary system. This separates a problem involving the testes from one involving the hormonal system that stimulates them.
That distinction is more informative than age alone. Two men of the same age may need different explanations for their findings because the underlying cause matters. The EAU recommends LH and FSH testing to help distinguish types of hypogonadism.
The guideline also describes functional hypogonadism as often associated with other health conditions or medicines. It is a diagnosis of exclusion after organic causes have been ruled out. It should not become a convenient label for any low result in an older man.
The EAU identifies sexual symptoms as the most specific group associated with late-onset hypogonadism. These include reduced libido and erectile dysfunction, along with fewer spontaneous or morning erections.
Fatigue and low mood also appear in the guideline's symptom list. So do reduced energy, concentration difficulties and sleep disturbances. However, the EAU cautions that symptoms are not exclusive to hypogonadism and must be interpreted within the wider clinical and biochemical picture.
The practical consequence is to describe the actual changes during a medical consultation rather than arrive with a diagnosis based on a symptom checklist.
The two explanations meet in the clinical assessment. Aging provides background context, while symptoms and laboratory findings help establish whether a deficiency syndrome is present. The EAU approach brings those elements together rather than treating age as either proof of disease or a reason to dismiss concerns.
The guideline identifies obesity and diabetes as important contributors to late-onset hypogonadism. It also points to other coexisting illnesses and overall poor health. Low testosterone can be more prevalent in specific clinical populations, including men with type 2 diabetes and metabolic disorders.
The EAU advises checking for diseases and medicines that could interfere with testosterone production or action. Other substances also belong in that review. This is why a medical history is part of interpreting a hormone result rather than a separate administrative exercise.
A useful clinical conversation therefore covers symptoms alongside existing conditions and current medicines. The aim is not simply to decide whether testosterone has changed. It is to understand what may be contributing to the pattern.
The EAU diagnostic approach combines compatible symptoms or signs with low morning total testosterone on at least two occasions. Measurements should use a reliable assay and be taken under fasting conditions.
The guideline recommends morning collection between 07:00 and 10:00. It cautions that non-fasting testing can underestimate total testosterone. For night-shift workers, the timing should account for sleep patterns rather than applying clock time without context.
An isolated low measurement taken under unsuitable conditions can therefore be misleading. The appropriate next question is whether confirmation under the recommended conditions is needed, not which treatment follows immediately. Testostra's explanation of how to approach an initial low result provides further context for that discussion.
The EAU presents 12 nmol/L (3.5 ng/mL) as a diagnostic threshold for late-onset hypogonadism. It places that threshold within an assessment of symptoms and repeated biochemical findings. The number is not a stand-alone diagnosis.
This gives the threshold a specific role: it helps organize clinical interpretation. It does not replace the history or the assessment of possible causes. Nor does crossing a numerical boundary by itself establish which management approach is appropriate.
The EAU recommends considering sex hormone-binding globulin, or SHBG, measurement and free-testosterone calculation when indicated. SHBG-related factors can affect how total testosterone should be interpreted.
This is especially relevant when total testosterone is near a decision threshold or a condition may affect SHBG. In those situations, a clinician may consider whether an additional measurement would clarify the result. The guideline does not call for every concerned man to receive the same broad hormone panel.
Understanding the relationship among total, free and bound testosterone can make the terms on a report easier to discuss. LH and FSH address another part of the assessment: helping identify the type of hypogonadism rather than simply adding more testosterone measurements.
The guideline's approach supports focused questions such as:
These are discussion points for qualified care rather than a self-directed testing protocol. A guide to the clinical evaluation process can help readers organize the information they bring to an appointment.
A confirmed diagnosis opens a discussion about causes and management. It does not make testosterone therapy the automatic next step. The EAU's recommendations depend on the clinical profile and the cause of the deficiency.
For overweight or obese men with hypogonadism, the EAU recommends weight loss and lifestyle changes as the first approach. This recommendation sits within its account of functional hypogonadism and associated health conditions.
The reasoning is broader than changing a laboratory number. Management considers the health context linked to the hormone findings. Decisions about that approach belong with the treating clinician rather than an age-based rule applied to everyone.
The EAU recommends against testosterone therapy in eugonadal men, meaning men with normal testosterone. It also recommends against using it to improve cognition, vitality or physical strength in aging men.
Those boundaries separate treatment of an assessed deficiency syndrome from attempts to treat aging as though it were itself a hormone disorder. A concern about energy or performance deserves an appropriate evaluation rather than a presumption that testosterone is the missing treatment.
The guideline states that testosterone therapy suppresses gonadotropins and spermatogenesis, or sperm production. It is contraindicated for men seeking fertility treatment. The EAU also recommends against using testosterone therapy for male infertility.
Fertility plans therefore belong in any clinician-led discussion of testosterone treatment. They are part of deciding whether an option fits the person's circumstances, not a detail to consider only after treatment begins.
Age-related change and hypogonadism belong in the same clinical picture, but the distinction rests on symptoms and properly interpreted testing within a person's wider health context.
Moving from the aging comparison to a discussion of laboratory results requires a clearer grasp of biomarkers, which Testostra explains through evidence-led reporting. Its coverage addresses confusion over total testosterone and free testosterone alongside SHBG, giving readers an educational basis for discussing a report without offering a diagnosis or hormone regimen.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra